Betamethasone dipropionate suppressed stimulated IL-1β secretion in THP-1-derived macrophages and mouse BMDMs, with reported IC50 values of 0.0029 and 0.0047 μM, respectively. These are cellular secretion endpoints. [1]
Macrophage IL-1β dose response and viability controls
Cell-based study · THP-1-derived macrophages and C57BL/6 mouse bone marrow-derived macrophages (BMDMs) [1]
BD reduced stimulated IL-1β secretion. Viability was assessed separately at higher concentrations and longer exposure; CC50 values are not therapeutic indices.
Literature-Reported Treatment Conditions
- Treatment concentration
- IL-1β assay: 10^-3–1 μM; viability assay: 2.5–320 μM
- Exposure duration
- BD pretreatment: 12 h in THP-1-derived macrophages and 1 h in BMDMs; viability: 24 h
- Method
- LPS/nigericin-stimulated secretion compared with no-BD stimulated and LPS-only controls
- Vehicle
- DMSO
- Reported limits
- Final DMSO percentage and exact biological n for Figure 1 are not specified in the reviewed caption. Section 2.9 defines n as biological replicates and technical triplicates for ELISA.
Methods and source locations
Compound reported in the paper: Betamethasone dipropionate; Compound label in the paper: BD
Reported reagent experiments; no confirmation of Adooq lot equivalence.
Section 3.1; Figure 1A–E; sections 2.1–2.4, 2.9
Secreted IL-1β in stimulated THP-1-derived macrophages: ELISA; author-reported fit — Section 3.1; Figure 1C
Secreted IL-1β in stimulated BMDMs: ELISA; author-reported fit — Section 3.1; Figure 1E
Cell viability after 24 h: CCK-8; author-reported fits — Section 3.1; Figure 1B,D
Pro-IL-1β expression and GR antagonist perturbation
Cell-based study · THP-1-derived macrophages and mouse BMDMs [1]
BD reduced pro-IL-1β transcript/protein without marked NLRP3 or caspase-1 reduction. Reduced p65 phosphorylation and partial RU486 reversal support a priming-pathway contribution; they do not establish a unique direct target.
Literature-Reported Treatment Conditions
- Treatment concentration
- BD: 0.01, 0.1 and 1 μM for expression/p65; BD 1 μM with RU486 1 or 10 μM
- Exposure duration
- BD pretreatment: 12 h (THP-1-derived cells) or 1 h (BMDMs); RU486 15 min before BD
- Method
- Stimulated macrophage expression assays and antagonist perturbation
- Vehicle
- DMSO
- Co-treatment
- RU486 only in antagonist arms
- Reported limits
- Final DMSO percentage and exact biological n are not specified in the reviewed figure captions. Mean ± SD per section 2.9.
Methods and source locations
Compound reported in the paper: Betamethasone dipropionate; Compound label in the paper: BD
Reported reagent experiments; no confirmation of Adooq lot equivalence.
Sections 3.3–3.4; Figures 3A–F and 4B–D; sections 2.2, 2.4–2.6, 2.9
Pro-IL-1β mRNA/protein; NLRP3 and caspase-1 protein: RT-qPCR and Western blot; GAPDH controls — Figure 3A–F; section 3.3
p-p65/total p65 and secreted IL-1β with GR antagonist: Western blot and ELISA; stimulated no-BD and BD-only comparators — Figure 4B–D; section 3.4
Negative inflammasome interaction and protease-protection tests
Biochemical assay · HEK293T overexpression system and corresponding protein-containing lysates [1]
Co-IP did not reveal disruption of tested NLRP3 interactions. DARTS did not detect protein protection. These limited negative assays do not exclude upstream or endogenous macrophage assembly effects.
Literature-Reported Treatment Conditions
- Treatment concentration
- Co-IP: 1 μM; DARTS: 50 μM
- Exposure duration
- DARTS BD incubation: 60 min; Co-IP BD exposure duration not specified in reviewed methods/caption
- Method
- Co-IP and DARTS followed by immunoblotting
- Vehicle
- DMSO
- Reported limits
- No positive binding-ligand control is shown in Figure 5; absence of protection does not establish absence of binding.
Methods and source locations
Compound reported in the paper: Betamethasone dipropionate; Compound label in the paper: BD
Reported reagent experiments; no confirmation of Adooq lot equivalence.
Section 3.5; Figure 5A–F; sections 2.6–2.7; discussion and limitations
NLRP3–NEK7, NLRP3–ASC and NLRP3–NLRP3 association: Co-IP with input and tag controls — Figure 5A–C; section 3.5
NLRP3, ASC and caspase-1 protease protection: DARTS; DMSO and no-pronase controls — Figure 5D–F; section 3.5; section 2.7